Effective for dates of service on and after August 1, 2022, the following current clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.

 

Access the clinical criteria document information.

 

Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of Oncology will be managed by AIM Specialty Health® (AIM).

 

ING-CC-0033

Xolair (omalizumab)

ING-CC-0042

Monoclonal Antibodies to Interleukin-17

ING-CC-0050

Monoclonal Antibodies to Interleukin-23

ING-CC-0124

Keytruda (pembrolizumab)

ING-CC-0186

Margenza (margetuximab-cmkb)

ING-CC-0209

Leqvio (inclisiran)

ING-CC-0210

Enjaymo (sutimlimab-jome)

ING-CC-0212

Tezspire (tezepelumab-ekko)

ING-CC-0213

Voxzogo (vosoritide)

 

2070-0522-PN-GA



Featured In:
May 2022 Anthem Provider News - Georgia